Clinical trials: GPC3 Positive Hepatocellular Carcinoma
Hepatoblastoma, Hepatocellular Carcinoma
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells.
- Conditions
- Hepatoblastoma, Hepatocellular Carcinoma, Wilms Tumor, Malignant Rhabdoid Tumor
- Trial name
- NCT06198296
- Testing
- 21.15.GPC3-CAR T cells
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Baylor College of Medicine
Hepatocellular Carcinoma (HCC)
CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma
In this single-center, single-arm, prospective, open-label Phase 1/2 study, the safety and efficacy of autologous GPC3-targeted chimeric antigen receptor (CAR) T-cell therapy will be evaluated in patients with GPC3-positive…
- Trial name
- NCT06641453
- Testing
- GPC3-CART cells, Fludarabine Phosphate for Injection, Cyclophosphamide for Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Liver Cell Carcinoma, Solid Tumor
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment.
- Conditions
- Liver Cell Carcinoma, Solid Tumor, Wilms Tumor, Malignant Rhabdoid Tumor
- Trial name
- NCT05103631
- Testing
- CATCH T cells
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Baylor College of Medicine
GPC3 Positive Hepatocellular Carcinoma, CAR-T Cell Immunotherapy
CAR-T Cell Immunotherapy for HCC Targeting GPC3
The purpose of this study is to preliminarily evaluate the safety and efficacy of CAR-T cell immunotherapy for GPC3 positive hepatocellular carcinoma.
- Trial name
- NCT02723942
- Testing
- CAR-T cell immunotherapy
- Where
- China
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Hepatocellular Carcinoma (HCC)
Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma
This is a single-arm, open-label study of safety, tolerability, and anti-cancer activity of SN301A (an off-the-shelf CAR NK cell therapy) in patients with glypican-3 (GPC3)-positive advanced hepatocellular carcinoma.
- Trial name
- SN301A (NCT06652243)
- Testing
- SN301A
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Solid Cancer, GPC3 Positive Hepatocellular Carcinoma
TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-G203 in patients with GPC3-positive recurrent or metastatic solid tumors who have…
- Trial name
- NCT07242417
- Testing
- TC-G203 cells treatment
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Beijing GoBroad Hospital
Hepatocellular Carcinoma
GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC
Patients with hepatocellular carcinoma (a type of primary liver cancers) are enrolls in this study. The cancer has progressed after standard treatment, or the patient cannot receive regular treatment.
- Trial name
- NCT04121273
- Testing
- CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Advanced Hepatocellular Carcinoma (HCC), GPC3 Positive Hepatocellular Carcinoma
An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.
- Trial name
- NCT07493044
- Testing
- Super CAR-T
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Guangzhou FineImmune Biotechnology Co., LTD.
Advanced Hepatocellular Carcinoma
To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307
To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307, Autologous Glypican 3 (GPC3) Targeted Chimeric Antigen Receptor T cell therapy in Patients with GPC3 Positive Advanced Hepatocellular Carcinoma who Have…
- Trial name
- NCT05783570
- Testing
- EU307 CAR-T Cell
- Where
- 4 sites in South Korea
- Volunteers
- 12 people
- Sponsor
- Eutilex
Hepatocellular Carcinoma
Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)
This study enrolls patients who have a type of cancer that arises from the liver called hepatocellular carcinoma. The cancer has come back, has not gone away after standard treatment, has spread outside of the liver or the…
- Trial name
- GLYCAR (NCT02905188)
- Testing
- GLYCAR T cells, Cytoxan, Fludarabine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Baylor College of Medicine
Solid Tumor (Excluding CNS), Hepatocellular Carcinoma
Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors
This Phase 1, open-label, non-randomized study will enroll adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors expressing glypican-3 (GPC3) to examine the safety, feasibility, and…
- Conditions
- Solid Tumor (Excluding CNS), Hepatocellular Carcinoma, Liver Cell Carcinoma, Liposarcoma
- Trial name
- INTERCEPT (NCT07224568)
- Testing
- SC-CAR.GPC3xIL15.21 CAR T cells
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Seattle Children's Hospital
Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of BGB-B2033 alone or in combination with tislelizumab, with or without…
- Conditions
- Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors
- Trial name
- NCT06427941
- Testing
- BGB-B2033, Tislelizumab, Bevacizumab
- Where
- 51 sites in United States, Brazil and 7 more
- Volunteers
- 630 people
- Sponsor
- BeOne Medicines
Hepatocellular Carcinoma
Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)
The goal of this clinical trial is to evaluate the safety and efficacy of anti-GPC3 scFv-41BB-CD3ζ-tEGFR chimeric antigen receptor (CAR)-modified T (CAR-T) cells in treating patients with GPC3-positive advanced hepatocellular…
- Trial name
- NCT03084380
- Testing
- Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xinqiao Hospital of Chongqing
Advanced Hepatocellular Carcinoma (HCC)
A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC)
This study is a single-centre, single-arm, open-label, dose-escalation exploratory study with single-dose administration. Its objective is to evaluate the safety, tolerability, dose, anti-tumor efficacy, and pharmacokinetic…
- Trial name
- NCT07039201
- Testing
- CG-102-12C
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- Zhejiang University
Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
This is a first-in-human (FIH), Phase 1/2, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in…
- Conditions
- Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung, Merkel Cell Carcinoma, Myxoid/Round Cell Liposarcoma
- Trial name
- DUET-1 (NCT05120271)
- Testing
- CAR-GPC3 T Cells
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 7 people
- Sponsor
- Sotio Biotech Inc.
Advanced Hepatocellular Carcinoma
B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma
This is an Open-label, Single Arm study to observe the safety and tolerability of B010-A in the treatment of advanced hepatocellular carcinoma.
- Trial name
- NCT05070156
- Testing
- Biological/Vaccine: Low-dose group, Biological/Vaccine: Mid-dose group, Biological/Vaccine: High-dose group
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Tongji University
HCC
Phase I Study of OriC902 in Treatment of Advanced HCC
This is a Phase I clinical study evaluating the safety, pharmacokinetics, and initial efficacy of a GPC3-targeted chimeric antigen receptor autologous T cell injection (OriC902) in GPC3-positive advanced hepatocellular carcinoma…
- Trial name
- NCT06891742
- Testing
- OriC902
- Where
- 2 sites in China
- Volunteers
- 44 people
- Sponsor
- Peking University
Neoplasms, Carcinoma, Hepatocellular
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
This is the first in human trial clinical study of AST-201 in patients with GPC3-positive advanced solid tumors. This study aims to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of…
- Conditions
- Neoplasms, Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms
- Trial name
- NCT06687941
- Testing
- AST-201
- Where
- 4 sites in South Korea
- Volunteers
- 70 people
- Sponsor
- Aptamer Sciences, Inc.